CD85j / LILRB1 Polyklonaler Antikörper

CD85j / LILRB1 Polyklonal Antikörper für WB, IHC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen(1)

Kat-Nr. : 26455-1-AP

Synonyme

LILRB1, ILT2, ILT 2, FLJ37515, CD85j

---

• 

  WB analysis using 26455-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 26455-1-AP (LILRB1 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Ramos using 26455-1-AP

  Ramos cells were subjected to SDS PAGE followed by western blot with 26455-1-AP (LILRB1 Antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human liver using 26455-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 26455-1-AP (LILRB1 antibody) at dilution of 1:400 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human liver using 26455-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 26455-1-AP (LILRB1 antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 26455-1-AP

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 26455-1-AP (LILRB1 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 26455-1-AP

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 26455-1-AP (LILRB1 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Daudi-Zellen, Ramos-Zellen
• Erfolgreiche Detektion in IHC: humanes Lebergewebe, humanes Tonsillitisgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:2000
• Immunhistochemie (IHC): IHC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• IHC: See 1 publications below

Produktinformation

26455-1-AP bindet in WB, IHC, ELISA CD85j / LILRB1 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: CD85j / LILRB1 fusion protein Ag24795
• Vollständiger Name: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
• Berechnetes Molekulargewicht: 71 kDa
• Beobachtetes Molekulargewicht: 71 and 110 kDa
• GenBank-Zugangsnummer: BC015731
• Gene symbol: LILRB1
• Gene ID (NCBI): 10859
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

LILRB1, also named as CD85j or ILT2, includes four C2 Ig domains binding HLA class I molecules in the extracellular region and a cytoplasmic domain containing four immunoreceptor tyrosine-based inhibition motifs (ITIM). LILRB1 is a surface glycoprotein detected on the surface of B cells, monocytes, dendritic cells, T cells and NK cells. The predicted MW of LILRB1 is 71 kDa and 26455-1-AP antibody recognizes the 71 and 110 kDa which might be the noncovalently linked monomer. (PMID:17601702; 15474475; 17549736; 24098421)

Publikationen

Species	Application	Title
human	IHC	Int Immunopharmacol; LILRB1+ immune cell infiltration identifies immunosuppressive microenvironment and dismal outcomes of patients with ovarian cancer; Authors - Xiaoyu Xu